Mochida Pharmaceutical Co. Ltd
Mochida Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals and healthcare products in Japan. It offers pharmaceuticals products for the treatment of cardiovascular, obstetrics, gynecology, dermatology, psychiatry, and gastroenterology, including Lialda, Omvoh, and Cortiment for the treatment of ulcerative colitis; Goofice and Movicol for the treatment of chronic constipation; Epadel … Read more
Mochida Pharmaceutical Co. Ltd (MFY) - Total Assets
Latest total assets as of March 2025: €160.12 Billion EUR
Based on the latest financial reports, Mochida Pharmaceutical Co. Ltd (MFY) holds total assets worth €160.12 Billion EUR as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mochida Pharmaceutical Co. Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Mochida Pharmaceutical Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Mochida Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Mochida Pharmaceutical Co. Ltd's total assets of €160.12 Billion consist of 74.7% current assets and 25.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 28.2% |
| Accounts Receivable | €31.62 Billion | 19.8% |
| Inventory | €33.30 Billion | 20.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Mochida Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mochida Pharmaceutical Co. Ltd's current assets represent 74.7% of total assets in 2025, an increase from 71.8% in 2014.
- Cash Position: Cash and equivalents constituted 28.2% of total assets in 2025, up from 25.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is inventory at 20.8% of total assets.
Mochida Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Mochida Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Mochida Pharmaceutical Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Mochida Pharmaceutical Co. Ltd generates 0.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Mochida Pharmaceutical Co. Ltd generates $ 3.55 in net profit.
Mochida Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.81 | 4.47 | 4.09 |
| Quick Ratio | 3.47 | 3.31 | 3.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €94.77 Billion | € 90.59 Billion | € 88.33 Billion |
Mochida Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Mochida Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.07 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | €160.12 Billion |
| Market Capitalization | $452.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mochida Pharmaceutical Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Mochida Pharmaceutical Co. Ltd's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Mochida Pharmaceutical Co. Ltd (2014–2025)
The table below shows the annual total assets of Mochida Pharmaceutical Co. Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €160.12 Billion | +0.83% |
| 2024-03-31 | €158.80 Billion | -0.02% |
| 2023-03-31 | €158.83 Billion | -2.64% |
| 2022-03-31 | €163.14 Billion | +0.83% |
| 2021-03-31 | €161.79 Billion | +2.73% |
| 2020-03-31 | €157.49 Billion | -0.96% |
| 2019-03-31 | €159.02 Billion | +2.56% |
| 2018-03-31 | €155.05 Billion | +4.50% |
| 2017-03-31 | €148.37 Billion | +7.74% |
| 2016-03-31 | €137.71 Billion | +7.96% |
| 2015-03-31 | €127.56 Billion | -2.38% |
| 2014-03-31 | €130.67 Billion | -- |